MIV Therapeutics Announces Landmark Patent Filings for Next-Generation Drug Delivery Technology

Strategic Insights -

MIV Therapeutics, a developer of next-generation biocompatible stent coatings and drug delivery technologies, has announced the filing of landmark US and international Patent Cooperation Treaty (PCT) patent applications for its advanced "Smart" drug delivery systems. The cutting-edge technology combines nanotechnology and pharmaceutical solutions to produce nano-to-micro sized particles that provide a highly versatile platform for localized delivery of drugs to treat a range of conditions.

Key Takeaways:

  • MIV Therapeutics has filed landmark patent applications for its advanced "Smart" drug delivery systems, which combine nanotechnology and pharmaceutical solutions to produce nano-to-micro sized particles for localized drug delivery.
  • The Smart III technology allows for the storage and delivery of one or more drugs within each particle's nano-layer, with controllable release patterns ranging from slow diffusion to a burst release.
  • The technology has broad application possibilities, including medical device coatings, tablets, capsules, and other drug delivery methods to treat a diverse range of diseases, such as cancer, HIV, and cardiovascular disease.
  • Advanced drug elution technologies are absorbing an increasingly large share of the global biotechnology marketplace, with a burgeoning domestic market for advanced drug delivery systems estimated to be $86 billion in 2007.
  • The Smart III patent filing represents the latest "Smart" proprietary technology developed by MIVT, with earlier members of the "Smart" family designed for advanced medical device coatings on implantable medical devices.
  • MIVT's "Smart" technologies are under development at the company's Vancouver-based research and development facility, with the proprietary technology entirely owned by MIVT.
  • The company has a Collaborative Research Agreement with the University of British Columbia and has received research and development grants from the Natural Sciences and Engineering Research Council of Canada (NSERC) and the National Research Council - Industrial Research Assistance Program (NRC-IRAP).
  • MIVT has a diverse and unique family of "Smart" drug delivery technologies designed to suit a broad range of implantable medical devices with highly customizable drug release profiles.

Statistics:

  • The U.S. Dept. of Commerce estimates a burgeoning domestic market for advanced drug delivery systems to be $86 billion in 2007.
  • The global market for advanced drug delivery systems is estimated to be over $150 billion.
  • The "Smart" technologies are under development at MIVT's Vancouver-based research and development facility with a team led by Dr. Dean-Mo Liu, Chief Scientist of Drug Delivery Technologies at MIVT.
  • The company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents.
  • Hydroxyapatite, a bioactive porous material, is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental, and other applications.

Sources:

  • MIV Therapeutics press release, [no date provided]
  • U.S. Dept. of Commerce, [no date provided]
  • MIV Therapeutics Investor Fact Sheet, [no date provided]
  • MIV Therapeutics website, [no date provided]
  • Trilogy Capital, [no date provided]